Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | GALR2 | O43603 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000235 | 0.93 | NR1H2 (0.46) | NR1H2NR1H3NAMPTCHRM5MEN1 | |
| SCHEMBL4684739 | 0.93 | NR1H2 (0.38) | NR1H2NR1H3NAMPTCHRM5MEN1 | |
| SCHEMBL4684834 | 0.92 | NR1H2 (0.55) | NR1H2NR1H3NAMPTCHRM5MEN1 | |
| SCHEMBL5746701 | 0.80 | NR1H2 (0.53) | NR1H2NR1H3CHRM5MAPT | |
| SCHEMBL4685753 | 0.80 | NR1H2 (0.41) | NR1H2NR1H3NAMPTALDH1A1MAPT | |
| SCHEMBL4690915 | 0.79 | NR1H2 (0.73) | NR1H2NR1H3NAMPTMEN1ALDH1A1 | |
| SCHEMBL3489506 | 0.79 | NAMPT (0.36) | NR1H2NR1H3NAMPTMEN1ALDH1A1 | |
| SCHEMBL4689233 | 0.77 | NR1H2 (0.60) | NR1H2NR1H3NAMPTGSK3AGSK3B | |
| SCHEMBL5613790 | 0.75 | P2RX3 (0.35) | MEN1ALDH1A1MAPTKMT2ATEAD4 | |
| SCHEMBL4684030 | 0.73 | NR1H2 (0.80) | NR1H2NR1H3MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646625-B1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | claimed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | claimed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | claimed |
| EP-1646625-B1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885NAMPT 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.